Filing Flows › China Pharma Holdings (CPHI) › Q4 2024
China Pharma Holdings (CPHI) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
China Pharma Holdings (CPHI) reported revenue of $1.1M for the fourth quarter 2024 (Q4 2024), -47% from a year earlier and +3% from the quarter before. Operating margin was -105.5%, net loss $1.2M (108.0% of revenue).
China Pharma Holdings, Q4 2024: revenue $1.1M (-47% year over year), operating margin -105.5%, net loss $1.2M, operating cash flow $238K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +3% | -47% |
| Operating profit | −$1.2M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | $238K | — | — |
| Free cash flow | $219K | — | — |
What changed
Revenue was $1.1M in Q4 2024, down 47% year over year and up 3% from the previous quarter.
Operating costs exceeded revenue by $1.2M, an operating margin of -105.5%. Total costs fell 30% while revenue fell 47%. The fastest-growing cost line was General & admin (+25%). The quarter ended with a net loss of $1.2M, wider than the previous quarter's $1.1M loss.
Operating cash flow was $238K. Non-cash charges added back $448K of depreciation and amortization. Working capital and other items added $1.0M. Capital expenditures of $20K left free cash flow of $219K.
Questions
What was China Pharma Holdings' revenue in the fourth quarter 2024?
China Pharma Holdings (CPHI) reported revenue of $1.1M for the fourth quarter 2024 (Q4 2024), -47% from a year earlier and +3% from the quarter before.
Was China Pharma Holdings profitable in the fourth quarter 2024?
Operating loss was $1.2M (-105.5% of revenue) and net loss $1.2M.